In addition, treatment of B-ALL cell lines with the P38 pathway inhibitor SB203580 resulted in noticeable downregulation of lactate level, glycolysis, glycolytic capacity, and HK2 expression (Figs. 4I–L and S4A). The gene discussed is HK2; the disease is acute lymphoblastic leukemia.